New opportunities for development of Vrsac-based Hemofarm - Stada and consortium of Bain Capital and Cinven to reach agreement on takeover

One of the leading pharmaceutical companies in the world, Stada, including Serbia's Hemofarm, has chosen a new path of growth, striving to strengthen its position in the current markets and penetrate new ones on all continents.

As the company reported, Stada's excellent results have enabled it to reach an agreement with one of the most reputable strategic partners in development, the consortium of Bain Capital and Cinven, following the global trend of consolidation through acquisition. The agreed price amounts to EUR 5.318 billion, and the agreement reached is also optimal in terms of protecting Stada's future, as well as that of its employees.

The press release reminds that Stada has recently marked a successful decade in Serbia and that the investments, exceeding EUR 200 million, have brought Hemofarm up to the level of the regional leader and the regional center for Southeast Europe.

– Ambitious plans for Stada's further development are also a new opportunity for Serbia's Hemofarm to grow – it was said.

As added, the leading managers of Stada will personally talk to employees in Vrsac about the new business model and opportunities on Wednesday, April 19, in line with the good German corporate practice.

Bain Capital Boston

Cinven Partners LLP

STADA Grupa

Hemofarm a.d. Vršac

acquisition of Stada